Coxon R - Search Results

1

Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic.

Dowall SD, Bosworth A, Rayner E, Taylor I, Landon J, Cameron I, Coxon R, Al Abdulla I, Graham VA, Hall G, Kobinger G, Hewson R, Carroll MW. Dowall SD, et al. Among authors: coxon r. Sci Rep. 2016 Jul 28;6:30497. doi: 10.1038/srep30497. Sci Rep. 2016. PMID: 27465308 Free PMC article.

2

Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.

Dowall SD, Jacquot F, Landon J, Rayner E, Hall G, Carbonnelle C, Raoul H, Pannetier D, Cameron I, Coxon R, Al Abdulla I, Hewson R, Carroll MW. Dowall SD, et al. Among authors: coxon r. Sci Rep. 2017 Jun 22;7(1):4099. doi: 10.1038/s41598-017-03910-7. Sci Rep. 2017. PMID: 28642489 Free PMC article.

3

Development and evaluation of an ovine antibody-based platform for treatment of Clostridium difficile infection.

Roberts A, McGlashan J, Al-Abdulla I, Ling R, Denton H, Green S, Coxon R, Landon J, Shone C. Roberts A, et al. Among authors: coxon r. Infect Immun. 2012 Feb;80(2):875-82. doi: 10.1128/IAI.05684-11. Epub 2011 Dec 5. Infect Immun. 2012. PMID: 22144483 Free PMC article.

4

Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb.

Casewell NR, Al-Abdulla I, Smith D, Coxon R, Landon J. Casewell NR, et al. Among authors: coxon r. Toxins (Basel). 2014 Aug 19;6(8):2471-82. doi: 10.3390/toxins6082471. Toxins (Basel). 2014. PMID: 25153254 Free PMC article.

5

Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.

Maynard-Smith M, Ahern H, McGlashan J, Nugent P, Ling R, Denton H, Coxon R, Landon J, Roberts A, Shone C. Maynard-Smith M, et al. Among authors: coxon r. Vaccine. 2014 Feb 3;32(6):700-5. doi: 10.1016/j.vaccine.2013.11.099. Epub 2013 Dec 14. Vaccine. 2014. PMID: 24342251 Free PMC article.

6

Inflammatory bowel disease and targeted oral anti-TNFα therapy.

Griffiths OR, Landon J, Coxon RE, Morris K, James P, Adams R. Griffiths OR, et al. Among authors: coxon re. Adv Protein Chem Struct Biol. 2020;119:157-198. doi: 10.1016/bs.apcsb.2019.08.009. Epub 2020 Jan 10. Adv Protein Chem Struct Biol. 2020. PMID: 31997768 Review.

7

Development of a simple, fluoroimmunoassay for paraquat.

Coxon RE, Rae C, Gallacher G, Landon J. Coxon RE, et al. Clin Chim Acta. 1988 Jul 29;175(3):297-305. doi: 10.1016/0009-8981(88)90106-4. Clin Chim Acta. 1988. PMID: 3416489

8

Development of separation fluoroimmunoassays for bendazac and 5-hydroxy bendazac.

Staley K, Coxon R, Gallacher G, Landon J. Staley K, et al. Among authors: coxon r. Ther Drug Monit. 1988;10(3):321-6. doi: 10.1097/00007691-198803000-00015. Ther Drug Monit. 1988. PMID: 3176111

9

Development of a radioimmunoassay for idazoxan hydrochloride.

Lynn AG, Coxon RE, Gallacher G, Landon J. Lynn AG, et al. Among authors: coxon re. J Pharm Biomed Anal. 1990;8(8-12):685-9. doi: 10.1016/0731-7085(90)80103-v. J Pharm Biomed Anal. 1990. PMID: 2100607

10

Development of fluoroimmunoassays for flecainide.

Coxon RE, Hodgkinson AJ, Sidki AM, Landon J, Gallacher G. Coxon RE, et al. Ther Drug Monit. 1987 Dec;9(4):478-83. doi: 10.1097/00007691-198712000-00020. Ther Drug Monit. 1987. PMID: 3122378

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

109 results

Search Page